February 28, 2007

Aida Pharmaceuticals' Researchers Publish Academic Article On Phase I Results Of Rh-Apo2L In Top Chinese Scholarly Journal

Aida Pharmaceuticals, Inc. (OTCBB: AIDA), one of Mainland China's leading pharmaceutical companies, today announced Company researchers have published an article entitled "Phase I Clinical Trial of Recombinant Human Apo-2 Ligand (Rh-Apo2L) in Patients with Advanced Cancer," in one of Mainland China's leading scholarly journals, Chinese Journal of New Drugs.

The article was written by Zhou Sheng-Yu, Chen Shan-Shan, Liu Peng, Luo Yang, Xing Pu-Yuan, He Jing, Liu Xiao, Li Duan and Feng Feng-Yi, scientists and medical professionals from the Department of Medical Oncology of the Cancer Hospital at the Chinese Academy of Medical Sciences and the Peking Union Medical College in Beijing's Laboratory of Pharmacy at the College of Pharmacy of Fudan University in Shanghai. These institutions were major participants in the Phase I clinical trial of Rh-Apo2L. The article is an overview of the Phase I clinical trial methodology and results.

Chairman of Aida Pharmaceuticals, Mr. Jin Biao, stated, "The inclusion of Aida Pharmaceuticals' research in the Chinese Journal of New Drugs is testament to academia's acceptance of the Phase I study of Rh-Apo2L. Rh-Apo2L was approved to begin Phase II trials by the State Food and Drug Administration of China at the end of last year, which makes Aida the first and only pharmaceuticals company in the world to receive approval for further clinical research of this kind of anticancer drug. We believe that Rh-Apo2L may be a revolutionary drug for the treatment of cancer and a catalyst for explosive growth for the Company."

About the Chinese Journal of New Drugs:

The Chinese Journal of New Drugs was founded in January of 1992, this monthly journal is a nationally distributed publication recognized by the pharmaceutical industry in China. It is administered by the State Food and Drug Administration (SFDA) and sponsored by several organizations including Chinese Pharmaceutical Association.

About Aida Pharmaceuticals:

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in Mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout Mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China.

Safe Harbor Statement:

Under the Private Securities Litigation Reform Act of 1995: This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov.

Aida Pharmaceuticals, Inc.

No comments: